Mike Matson

Do you think that's representative of the growth in patients? Or are you getting some kind of pricing benefit up there on top of that?

with the new N30i with that fabric over the straps, is that a technology that you can apply to other masks in your portfolio

with the rollback or potential rollback of the ethylene oxide regulations under the new administration, what does that mean for STERIS?

What is your expectation for the USMCA renegotiation this year? And what have you assumed in your guidance with regard to that?

if you've been paying tariffs for basically all four quarters of '26, does that imply that kind of any incremental tariff impact in '27 will be small

it's been I think it's been a few years since you've done an acquisition

can you just give us an update on your capacity there? And are you currently capacity constrained?

I'm just wondering if you could give us any more detail around geographies, types of customers, hospitals versus ASCs, product lines

there's been some cuts in vaccine spending, kind of reduced recommendations there. And then, broadly, we're seeing kind of a pullback

I assume that's mainly driven by working capital. Is that right

your cash flow guidance is a little bit down from '25. I know you called out the working capital improvement

I think you've talked about that being sort of a growth driver in the past. Is that still the case

are you hearing any concerns about potential policy changes with the new administration

bioprocessing, I just was wondering if you can give us a sense of how much of AST that is

is this just sort of lagging kind of some of the other, I guess, costs? Or is there something else going on here

is the idea that, that would -- those products once they're approved and everything largely be sold through the Inari sales team

Last year, you said you would fully absorb that. Is that the case again this year? And, you know, is there any ability to mitigate any of the impact

with Mako four, are you getting pricing increase relative to the older version

the PEERLESS II trial, just can you give us an update on where things stand with that and when we could potentially see the results

is this a sign that Stryker has interest in kind of the broader advanced wound care market

you mentioned this Broadway large for catheter. Can you just talk a little bit more about the timing on that?

I think shoulders have also started to move into the ASC setting, total shoulders. So what are you seeing there

you're calling out a slightly unfavorable foreign exchange impact. Can you maybe explain what that means? Because I guess I thought that this was constant currency growth?

I don't know if you guys are willing to disclose how much you got for that business? I assume we'll see something in the second quarter cash flow statement

how much of your manufacturing is coming from either of those two countries? And how much flexibility do you have to move production elsewhere

how the Mako and Enabling Technologies partnership will sort of work. I know one of your competitors tried to be something similar when they spun out their Spine business

can you maybe just talk about what you're hearing from the FDA in terms of iodine coatings, what you're going to have to do to get that launched